These forward-looking statements include, but are not limited to: statements concerning Skye's future plans and prospects, any expectations regarding the safety, efficacy, tolerability or combinability of nimacimab, including based on preclinical diet induced obesity (DIO) studies and clinical studies, the timing of the receipt of final data from our clinical studies, the potential market opportunities, the timing and clinical strategy for nimacimab, the planned timing of Skyes anticipated milestones for nimacimab and the companys cash runway
Other vial sizes and concentrations are tabulated in the reconstitution section above
Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2023 Zhang, Hou, Li, Deng, Yang, Li, Yao, Yang, Lin, Liao, Wang, Liu, Tan, Wan and Shuai
Practical takeaway: Patients should not assume that a clinic or pharmacy can dispense a newly compounded peptide solely because a news story reports a favorable panel vote
When clinically appropriate, InjectCo may incorporate compounded medications sourced from a licensed 503B outsourcing pharmacy
